Would you consider using trastuzumab deruxtecan in a patient with progressive HR+ breast cancer that is HER2 2+ with prior history of cell cycle inhibitor related pneumonitis?
Answer from: Medical Oncologist at Academic Institution
In DESTINY-Breast04, about 70% of patients were CDK4/6i treated but were excluded if they had a history of ILD/pneumonitis. So, we don't know if this patient is at higher risk of pneumonitis with tastuzumab deruxetecan. I would consider it if her previous pneumonitis was mild and fully resolved with...
Sign in or Register to read more